<DOC>
	<DOCNO>NCT00079404</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin treating young patient relapsed refractory solid tumor leukemia . Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Young Patients With Relapsed Refractory Solid Tumors Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) recommend phase II dose 17-AAG administered 60 120-minute intravenous infusion day 1 , 4 , 8 , 11 , 21-day course , child refractory solid tumor relapse leukemia . II . To define describe toxicity 17-AAG administered schedule . III . To characterize pharmacokinetics 17-AAG child refractory cancer . SECONDARY OBJECTIVES : I . To preliminarily define antitumor activity 17-AAG within confines phase I study . II . To assess biologic activity 17-AAG . III . To examine role CYP3A5 polymorphisms pharmacologic clinical phenotype observe follow administration 17-AAG child , within confines phase 1 study . OUTLINE : This dose-escalation , multicenter study . Patients solid tumor receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 60-120 minute day 1 , 4 , 8 , 11 . Treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 6 additional patient leukemia receive 17-AAG MTD . If 6 patient tolerate regimen , another 6 leukemia patient receive 17-AAG IV 60 minute day 1 , 4 , 8 , 11 , 15 , 18 . Treatment repeat every 28 day 17 course absence disease progression unacceptable toxicity . Patients follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Histologically confirm diagnosis solid tumor leukemia document M3 marrow Histologic confirmation intrinsic brain stem tumor require Relapsed refractory disease No known curative therapy In patient CNS tumor , neurologic deficit must stable least past week Performance status Karnofsky 50100 % ( &gt; 10 year age ) Performance status Lansky 50100 % ( ≤ 10 year age ) For patient solid tumor : Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 ( transfusion independent ) Hemoglobin ≥ 8.0 g/dL ( may receive RBC transfusion ) For patient leukemia : Platelet count ≥ 20,000/mm^3 ( may receive platelet transfusion ) Hemoglobin ≥ 8.0 g/dL ( may receive RBC transfusion ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT ≤ 2.5 time ULN Albumin ≥ 2 g/dL Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine base age follow : ≤ 0.8 mg/dL ≤ 5 year age ≤ 1.0 mg/dL &gt; 5 year ≤ 10 year age ≤ 1.2 mg/dL &gt; 10 year ≤ 15 year age ≤ 1.5 mg/dL &gt; 15 year ≤ 21 year age No uncontrolled infection No prior severe allergy egg No situation would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception At least 7 day ( window adverse effect pass ) since prior biologic therapy recover At least 7 day since prior hematopoietic growth factor At least 2 month since prior stem cell transplantation evidence graftvshost disease No concurrent hematopoietic growth factor No concurrent biologic therapy No concurrent immunotherapy At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) recover No concurrent chemotherapy No concurrent steroid therapy At least 2 week since prior local palliative radiotherapy ( small port ) At least 3 month since prior total body irradiation craniospinal radiotherapy At least 3 month since prior radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy Recovered prior radiotherapy No concurrent radiotherapy No concurrent investigational drug No concurrent anticancer agents No concurrent phenytoin phenobarbital No concurrent warfarin</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>